These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 206089)

  • 1. Experimental and clinical studies on bromocriptine in the Parkinsonian syndrome.
    Goldstein M; Lieberman A; Battista AF; Lew JY; Matsumoto Y
    Acta Endocrinol Suppl (Copenh); 1978; 216():57-66. PubMed ID: 206089
    [No Abstract]   [Full Text] [Related]  

  • 2. Bromocriptine, lergotrile: the antiparkinsonian efficacy and the interaction with monoaminergic receptors.
    Goldstein M; Lieberman A; Battista AF; Lew JY; Hata F
    Pharmacology; 1978; 16 Suppl 1():143-9. PubMed ID: 25445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of parkinsonian syndromes by bromocriptin].
    Gautier JC; Durand JP
    Nouv Presse Med; 1977 Jan; 6(3):171-4. PubMed ID: 319421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemiparkinsonism. A human model for studying dopaminergic supersensitivity.
    Trabucchi M; Albizzati MG; Frattola L; Scarlato G
    Arch Neurol; 1979 Apr; 36(4):246-8. PubMed ID: 426672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa.
    Rinne UK; Marttila R
    Ann Neurol; 1978 Sep; 4(3):263-7. PubMed ID: 718139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopaminephilic properties of ergot alkaloids.
    Goldstein M; Lew JY; Nakamura S; Battista AF; Lieberman A; Fuxe K
    Fed Proc; 1978 Jun; 37(8):2202-6. PubMed ID: 26607
    [No Abstract]   [Full Text] [Related]  

  • 9. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
    Gawel M; Riopelle R; Libman I; Bouchard S
    Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison between lergotrile and bromocriptine in parkinsonism.
    Teychenne PF; Pfeiffer RF; Bern SM; McInturff D; Calne DB
    Ann Neurol; 1978 Apr; 3(4):319-24. PubMed ID: 666273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Sydney multicentre study of Parkinson's disease. The first 18 months.
    Hely MA; Morris JG; Rail D; O'Sullivan DJ; Williamson PM; Genge S; Reid WG; Broe GA
    Med J Aust; 1987 Feb; 146(4):195-8. PubMed ID: 3553878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current treatment of Parkinsonian syndrome].
    Lechner H; Bertha G; Ott E
    Med Welt; 1980 Oct; 31(40):1444-6. PubMed ID: 7464500
    [No Abstract]   [Full Text] [Related]  

  • 13. Parkinsonism from methanol poisoning: benefit from treatment with anti-Parkinson drugs.
    Davis LE; Adair JC
    Mov Disord; 1999 May; 14(3):520-2. PubMed ID: 10348484
    [No Abstract]   [Full Text] [Related]  

  • 14. Parkinson's disease improvement after the addition of levodopa-carbidopa to anticholinergic treatment. An open controlled study.
    Agnoli A; Ruggieri S; Denaro A; Lelli A
    Acta Neurol (Napoli); 1978 Oct; 33(5):436-42. PubMed ID: 756675
    [No Abstract]   [Full Text] [Related]  

  • 15. Dystonia-Parkinson syndrome: differential effects of levodopa and dopamine agonists.
    Klawans HL; Paleologos N
    Clin Neuropharmacol; 1986; 9(3):298-302. PubMed ID: 3719575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Letter: Effect of bromocryptine on the fluctuations following dopa therapy. On-off phenomenon in parkinsonian patients].
    Frattola L; Albizzati MG; Spano PF; Trabucchi M
    Nouv Presse Med; 1976 Aug 28-Sep 4; 5(28):1761. PubMed ID: 958891
    [No Abstract]   [Full Text] [Related]  

  • 17. Experimental neuropathy with Parkinson-like muscular rigidity. A suitable model for testing dopaminergic agonists and neuroleptic drugs.
    Halbhübner K; Herken H; Loos D
    Arzneimittelforschung; 1978; 28(10):1743-52. PubMed ID: 39569
    [No Abstract]   [Full Text] [Related]  

  • 18. Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause.
    Figà-Talamanca L; Gualandi C; Di Meo L; Di Battista G; Neri G; Lo Russo F
    Neurology; 1985 Feb; 35(2):258-61. PubMed ID: 3969217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of parkinsonism.
    Calne DB; Teychenne PF; Pfeiffer RF
    Adv Exp Med Biol; 1977; 90():49-61. PubMed ID: 930750
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors.
    Gomez-Mancilla B; Boucher R; Gagnon C; Di Paolo T; Markstein R; Bédard PJ
    Mov Disord; 1993 Apr; 8(2):144-50. PubMed ID: 8474480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.